ONCSinactive

ONCOSEC MEDICAL INC

Healthcare·Oncology·Phase 2
Oncology

ONCOSEC MEDICAL INC (ONCS): 1 pipeline candidate. Updated within the last hour.

6.4/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for ONCOSEC MEDICAL INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

—

Quarterly Burn

$6.6M

Runway

—

Revenue

—

Pipeline (1 candidate)

DrugPhase
tavoPhase 2
·CEO: Robert H. Arch

Frequently asked questions

How many drug candidates are in ONCOSEC MEDICAL INC's pipeline?

ONCOSEC MEDICAL INC (ONCS) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is ONCOSEC MEDICAL INC's lead drug candidate?

ONCOSEC MEDICAL INC's most advanced tracked candidate is tavo (Phase 2) for Metastatic melanoma.

Who is the CEO of ONCOSEC MEDICAL INC?

Robert H. Arch is the chief executive officer of ONCOSEC MEDICAL INC (ONCS).

Get the full picture on ONCOSEC MEDICAL INC

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar